 O'r pethau rhoda't, sgwrs reisyn am y sgwrs os eich infimol o'r meddwlion arminsihol a ty Passol yn myelonu. O'r pethau'r meddwlion ar de chael amddangos eu meddwlion yn eu cyfrifiadau i'r meddwlion ar gyfer mae'r meddwlion yma, ac mae allan o'r meddwlion bryd o'r myelon o theropau a meddwlion o'r meddwlion fydd yn ysgrifennol. Fethau'r meddwlion o'r meddwlion ar gyfer amendmentr yn ein cwmnaeth eich meddwlion. the EMNO2 study in Europe, and then the IFM 2009 study, also run in Europe, and the determination study, which has had very similar design to IFM 2009, but run in the United States. And the difference between the IFM study and determination was really the length of Lenelidomide maintenance given after the autologous stem cell transplant. But addressing the question of transplant itself, so all of these studies have shown that having a stem cell transplant as part of first line therapy is able to induce a deeper remission than not having a transplant at that time, and is also associated with longer duration of remission. So a longer period of time before myeloma comes back for patients. And so that's really valuable knowledge because we know that that first remission duration is often the time when patients feel most well and are able to get on with the things that they enjoyed doing prior to their diagnosis, perhaps going back to work if they were previously working and so on. And so that first duration of remission is really important to patients. So nevertheless it's important to remember that having an autologous stem cell transplant is not a minor undertaking for patients. It is associated with significant side effects and often requires the patient to be in hospital, potentially away from their family, and with the risk of infection during that time as well. So I very much hope that moving forward some of the newer immunotherapies that we are now studying in clinical trials in later lines of therapy may be able to move forward into earlier lines of therapy and perhaps even replace transplant in the future so that we can try and improve the side effects that patients are experiencing in that initial treatment period.